My mother told me that her dog was on this med and so was Mel Gibson. So I ran off to see what the dog and Mel are on. Seems that this med is also used for CFIDS to help with cognitive issues.
Has anyone tried this med? Experiences on this please????
------------------------------------------------------------------------------------------------
"Selegiline (l-deprenyl, Eldepryl) is a drug used for the treatment of early-stage Parkinson's disease, depression and senile dementia. In normal clinical doses it is a selective irreversible MAO-B inhibitor, however in larger doses it loses its specificity and also inhibits MAO-A. Dietary restrictions are common for MAOI treatments, but special dietary restrictions for lower doses have been found to be unnecessary[1], and dietary restrictions appear to be unnecessary at standard doses when selegiline is taken as Emsam, the transdermal patch form, as no adverse events due to diet have ever been reported with Emsam.[2] The drug was researched by Jozsef Knoll et al. (Hungary). Selegiline belongs to a class of drugs called phenethylamines. Selegiline consists of a l-desoxyephedrine (levomethamphetamine) skeleton with a propargyl group attached to the nitrogen atom"
--------------------------------------------------------------------------------------------
Pharmacopsychiatry
http://content.karger.com/ProdukteD...oduktNr=224082&Ausgabe=226268&ArtikelNr=26494
Vol. 37, No. 3, 1998
Free Abstract Article (References) Article (PDF 191 KB)
________________________________________
Pharmacopsychiatry
Original Paper
Single-Blind, Placebo Phase-in Trial of Two Escalating Doses of Selegiline in the Chronic Fatigue Syndrome
Benjamin H. Natelsona, Joseph Cheua, Nancy Hilla, Michael Bergena, Leo Korna, Thomas Dennyb, Kristina Dahla
CFS Center and Departments of
a Neurosciences and
b Pediatrics, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, N.J., USA
Address of Corresponding Author
Neuropsychobiology 1998;37:150-154 (DOI: 10.1159/000026494)
________________________________________
Key Words
Chronic fatigue syndrome
Selegiline
Monoamine oxidase inhibitor
________________________________________
Abstract
Aim: To perform a clinical trial of selegiline in 25 patients with chronic fatigue syndrome (CFS) where patients were told they would receive placebo or active agent at different times during the 6-week trial. We chose selegiline, a specific monoamine oxidase (MAO) B receptor inhibitor, because a prior trial of low-dose phenelzine, a nonspecific MAO inhibitor, showed a small but significant therapeutic effect. Methods: Questionnaires comprised of 19 tests of mood, fatigue, functional status and symptom severity were collected at the start and end of the trial as well as 2 weeks after its start. The trial was done in three 2-week blocks: in the first, 2 placebo pills were given per day; in the next, one 5-mg tablet of agent and one placebo were given per day, and in the last, a 5-mg tablet of agent was given twice a day. The plan was to compare the changes in the 19 tests during the placebo phase to those found in the active treatment phase in 19 patients completing the trial. Findings: Significant improvement in 3 variables tension/anxiety, vigor and sexual relations was found. A significant pattern of improvement compared to worsening was found for the 19 self-report vehicles during active treatment as compared with placebo treatment. Evidence for an antidepressant effect of the drug was not found. Conclusions: Selegiline has a small but significant therapeutic effect in CFS which appears independent of an antidepressant effect.________________________________________
Author Contacts
Benjamin H. Natelson, MDDepartment of Neurosciences, New Jersey Medical School
88 Ross Street
East Orange, NJ 07018 (USA)
Tel. +1 (201) 676 1000, ext. 1414, Fax +1 (201) 676 4461, E-Mail bhn@nbunj.jvnc.net
________________________________________
Article Information
Number of Print Pages : 5
Number of Figures : 0, Number of Tables : 1, Number of References : 28
2010 S. Karger AG, Basel
Has anyone tried this med? Experiences on this please????
------------------------------------------------------------------------------------------------
"Selegiline (l-deprenyl, Eldepryl) is a drug used for the treatment of early-stage Parkinson's disease, depression and senile dementia. In normal clinical doses it is a selective irreversible MAO-B inhibitor, however in larger doses it loses its specificity and also inhibits MAO-A. Dietary restrictions are common for MAOI treatments, but special dietary restrictions for lower doses have been found to be unnecessary[1], and dietary restrictions appear to be unnecessary at standard doses when selegiline is taken as Emsam, the transdermal patch form, as no adverse events due to diet have ever been reported with Emsam.[2] The drug was researched by Jozsef Knoll et al. (Hungary). Selegiline belongs to a class of drugs called phenethylamines. Selegiline consists of a l-desoxyephedrine (levomethamphetamine) skeleton with a propargyl group attached to the nitrogen atom"
--------------------------------------------------------------------------------------------
Pharmacopsychiatry
http://content.karger.com/ProdukteD...oduktNr=224082&Ausgabe=226268&ArtikelNr=26494
Vol. 37, No. 3, 1998
Free Abstract Article (References) Article (PDF 191 KB)
________________________________________
Pharmacopsychiatry
Original Paper
Single-Blind, Placebo Phase-in Trial of Two Escalating Doses of Selegiline in the Chronic Fatigue Syndrome
Benjamin H. Natelsona, Joseph Cheua, Nancy Hilla, Michael Bergena, Leo Korna, Thomas Dennyb, Kristina Dahla
CFS Center and Departments of
a Neurosciences and
b Pediatrics, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, N.J., USA
Address of Corresponding Author
Neuropsychobiology 1998;37:150-154 (DOI: 10.1159/000026494)
________________________________________
Key Words
Chronic fatigue syndrome
Selegiline
Monoamine oxidase inhibitor
________________________________________
Abstract
Aim: To perform a clinical trial of selegiline in 25 patients with chronic fatigue syndrome (CFS) where patients were told they would receive placebo or active agent at different times during the 6-week trial. We chose selegiline, a specific monoamine oxidase (MAO) B receptor inhibitor, because a prior trial of low-dose phenelzine, a nonspecific MAO inhibitor, showed a small but significant therapeutic effect. Methods: Questionnaires comprised of 19 tests of mood, fatigue, functional status and symptom severity were collected at the start and end of the trial as well as 2 weeks after its start. The trial was done in three 2-week blocks: in the first, 2 placebo pills were given per day; in the next, one 5-mg tablet of agent and one placebo were given per day, and in the last, a 5-mg tablet of agent was given twice a day. The plan was to compare the changes in the 19 tests during the placebo phase to those found in the active treatment phase in 19 patients completing the trial. Findings: Significant improvement in 3 variables tension/anxiety, vigor and sexual relations was found. A significant pattern of improvement compared to worsening was found for the 19 self-report vehicles during active treatment as compared with placebo treatment. Evidence for an antidepressant effect of the drug was not found. Conclusions: Selegiline has a small but significant therapeutic effect in CFS which appears independent of an antidepressant effect.________________________________________
Author Contacts
Benjamin H. Natelson, MDDepartment of Neurosciences, New Jersey Medical School
88 Ross Street
East Orange, NJ 07018 (USA)
Tel. +1 (201) 676 1000, ext. 1414, Fax +1 (201) 676 4461, E-Mail bhn@nbunj.jvnc.net
________________________________________
Article Information
Number of Print Pages : 5
Number of Figures : 0, Number of Tables : 1, Number of References : 28
2010 S. Karger AG, Basel